New global registry tracks safety of common blood thinners in APS patients
NCT ID NCT04262492
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is creating a global registry of 500 adults with antiphospholipid syndrome (APS) who are taking direct oral anticoagulants (DOACs) like rivaroxaban or apixaban. Researchers will track rates of recurrent blood clots and bleeding over at least 6 months. The goal is to gather real-world safety information for this specific patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, edoxaban)
- What this could lead to
- If successful, this registry could provide clearer safety data on using DOACs in low-risk APS patients, potentially guiding future treatment decisions.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be limited by patient selection and real-world variability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTICOAGULANTS CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stéphane Zuily
RECRUITINGNancy, 54500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood platelet trends may reveal hidden risk in autoimmune disease
- Can a new device suck out deadly lung clots?
- Can a sedative help rebuilt tissue survive after cancer surgery?
- Immune clues in the blood may foretell heart trouble
- Can a simple blood test tell two forms of a clotting disorder apart?
- Your DNA could determine which heart drug works best